Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature

Yosuke Mai1, Wataru Nishie1*, Kazumasa Sato2, Moeko Hotta1, Kentaro Izumi1, Kei Ito2, Kazuyoshi Hosokawa3 and Hiroshi Shimizu1

1 Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan; 2 Department of Dermatology, JR Sapporo Hospital, Sapporo, Japan; 3 Department of Dermatology, Shinkotoni Skin Care Clinic, Sapporo, Japan

Bullous pemphigoid (BP) is a common autoimmune blistering disease in which autoantibodies mainly target the hemidesmosomal component BP180 (also known as type XVII collagen) in basal keratinocytes. Various triggering factors are known to induce BP onset, including radiotherapy, burns, ultraviolet exposure, surgery, and the use of dipeptidyl peptidase-IV inhibitors (DPP4i), which are widely used antihyperglycemic drugs. Here, we present a case of BP triggered by a thermal burn under medication with DPP4i. A 60-year-old man with type II diabetes had been treated with the DPP4i linagliptin for 1 year. After the right forearm experienced a thermal burn, blisters developed around the burned area and gradually spread over the whole body with the production of autoantibodies targeting the non-NC16A domain of BP180. The diagnosis of BP was confirmed by immunohistopathological examination. Upon withdrawal of linagliptin and treatment with topical steroid and minocycline, complete remission was achieved after 4 months. Previously, 13 cases of BP that developed after thermal burns have been reported, and our case shared some of the clinical features of these thermal burn-induced BP cases. Interestingly, the present case also showed the typical clinical, histopathological, and immunological features of the non-inflammatory type of DPP4i-associated BP (DPP4i-BP). Although the pathogenesis of BP remains uncertain, the present case suggests that DPP4i may trigger the onset of BP similarly to a thermal burn. In addition, the clinical and histopathological features of DPP4i-BP may be distinct from other types of BP.

Keywords: bullous pemphigoid, dipeptidyl peptidase-IV inhibitor, dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid, burn, cellulitis, autoimmune disease, autoantibodies, physical factors

CASE PRESENTATION

A 60-year-old man with type II diabetes was referred to our department due to blisters and erosions over the whole body. He had been treated with linagliptin, a dipeptidyl peptidase-IV inhibitor (DPP4i), for 1 year. Two months before the referral, he had suffered a deep, 7-cm-long dermal burn on the right forearm from a kitchen accident. Within 2 days after the burn, blisters had appeared

Abbreviations: BP, bullous pemphigoid; DPP4i, dipeptidyl peptidase-IV inhibitor; DPP4i-BP, dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid; CLEIA, chemiluminescent enzyme immunoassay; ELISA, enzyme-linked immunosorbent assay; HLA, human leukocyte antigen.
on the right forearm, which were treated with a topical antibiotic ointment. However, multiple blisters and erosions gradually developed over the body over the course of 2 months. Physical examination revealed tense blisters and erosions of 5 mm to 2 cm in diameter with circumscribed erythematous lesions predominately on the right forearm (Figure 1A). Blisters and erosions less than 5 mm in diameter without erythema were found on the face, trunk, and the left leg (Figure 1B). Although BP180 NC16A chemiluminescent enzyme immunoassay (CLEIA) was negative (5.9 U/mL; normal, <9.0 U/mL), histopathological examination of the blister showed sub-epidermal blister formation with eosinophilic infiltration in the dermis (Figure 1C). Direct immunofluorescence showed linear deposition of IgG autoantibodies along the dermal–epidermal junction (Figure 1D), and 1 M NaCl-split skin indirect immunofluorescence revealed circulating IgG autoantibodies reacting with the epidermal side of the artificial blisters (not shown). Notably, enzyme-linked immunosorbent assay (ELISA) using full-length recombinant BP180 was positive (index value, 41.8; normal, <4.64) (1). Based on these findings, the diagnosis of bullous pemphigoid (BP) was made. Linagliptin was withdrawn 2 days after the referral, and treatment with a topical steroid and minocycline at 100 mg/day was started. His skin lesions gradually improved, and ELISA with full-length recombinant BP180 became negative (index value, 1.03). Complete remission of therapy was achieved 4 months later (Figure 2). Although no DPP4i was re-administered, blisters appeared on the left forearm 16 months later, when he developed cellulitis on the right leg. The histopathology of the blister showed sub-epidermal blistering with scant eosinophilic infiltration in the dermis (not shown), which was consistent with BP. BP180 NC16A CLEIA was still negative (<3 U/mL). Topical steroid, minocycline at 200 mg/day, and nicotinamide at 1,500 mg/day were initiated, and the lesions completely resolved 2 months later. At 2 months after the cessation of treatment, no recurrence was observed (Figure 2).

INTRODUCTION

Bullous pemphigoid is a common autoimmune blistering disease in which autoantibodies target the hemidesmosomal components BP180 (also known as type XVII collagen) and/or BP230 at the dermal–epidermal junction (3). Clinically, tense blister formation associated with itchy urticarial erythema is typically observed in BP patients, and sub-epidermal blister formation with eosinophilic infiltration is histopathologically observed (3). Although the etiology of BP remains unclear, various factors, including radiotherapy, burns, ultraviolet (UV) exposure, trauma, surgical procedures, topical medications, and infections are known to trigger the onset of the disease (4, 5). Recently, emerging evidence reports that the use of DPP4i, which are widely used to treat patients with diabetes mellitus, increases the risk of BP onset (6–9).

DISCUSSION

Herein, we report a case of BP in which a thermal burn triggered the onset of the disease. As shown in Table 1, various BP-inducing physical factors, including radiation (5, 10–18), UV radiation...
TABLE 1 | List of physical triggering factors for bullous pemphigoid.

| Triggering factor       | No. of cases |
|-------------------------|--------------|
| Radiation               | 38           |
| UV                      | 37           |
| PUVA                    | 13           |
| UVB                     | 5            |
| Goeckerman              | 4            |
| PUVA and UVB            | 3            |
| UVA                     | 3            |
| Sunlight                | 2            |
| PUVA and sunlight       | 1            |
| PUVASOL                 | 1            |
| Ingram                  | 1            |
| Unknown wavelength      | 4            |
| Surgical wound          | 22           |
| Ostomy                  | 19           |
| Colostomy               | 10           |
| Gastrostomy             | 5            |
| Ileostomy               | 2            |
| Urostomy                | 2            |
| Burn                    | 14           |
| Thermal burn            | 13           |
| Chemical burn           | 1            |
| Skin graft              | 6            |
| Other                   | 11           |
| Scratching              | 3            |
| Injury                  | 2            |
| Dye injection           | 1            |
| Mechanical trauma       | 1            |
| Insect bite             | 1            |
| Revascularization       | 1            |
| Photodynamic therapy    | 1            |
| Hernia                  | 1            |

(5, 19–30), surgical wounds (5, 31–45), ostomy (31, 46–51), burns (5, 52–62), skin grafts (59, 63–67), and other trauma (5, 68–72) have been reported in the English literature. Regarding thermal burns, 13 cases have been reported (Table 2) (5, 52–61). Notably, in contrast to the present case, none of those 13 cases relapsed (5, 52–61) suggesting that the present case had a unique clinical course.

Interestingly, linagliptin, which is a DPP4i, was administered to our case until the onset of BP. DPP4i-associated BP (DPP4i-BP) is a unique, recently reported subtype of BP that develops with the administration of DPP4i medications such as vildagliptin, sitagliptin, and linagliptin (6–9). DPP4i-BP tends to show scant erythema and low levels of autoantibodies targeting the NC16A domain of BP180 or the absence of such autoantibodies (1, 73). In our case, BP developed after 1 year of DPP4i administration, in which erythema was scanty observed and autoantibodies specifically targeted the non-NC16A domain of BP180. In addition, complete remission was achieved after the withdrawal of DPP4i and the initiation of treatment with topical steroid and systemic minocycline. Histopathologically, eosinophilic infiltration was not evident. These characteristics closely resembled those of the non-inflammatory type of DPP4i-BP (1, 73); therefore, DPP4i use may also be involved in the development of the disease. It should be noted that a recent study reported that 18% of DPP4i-BP cases relapsed even after the withdrawal of DPP4i (7). Although the immunohistopathological results were uncertain, the present case developed BP-like blisters when he suffered from cellulitis 16 months after complete remission, indicating that DPP4i was also associated with the BP onset in the present case.

The pathogenic mechanisms of the physical trigger for BP onset remain elusive. The physical factors cause tissue destruction that activates the inflammatory process, which may result in the observed auto-reactivity to basement membrane proteins, including BP180 (5). Alternatively, basement membrane proteins may be altered as a result of physical factors (74) resulting in immunogenicity with increased affinity to certain human leukocyte antigen (HLA) alleles (75). Notably, 86% of cases of the non-inflammatory type of DPP4i-BP carried HLA-DQB1*03:01 (73). Although the HLA allele was not examined, it is likely that the present case had a genetic propensity to the breakdown of self-tolerance to BP180.
CONCLUDING REMARKS

In conclusion, we reported a case of BP induced by a thermal burn. Interestingly, the patient received DPP4i and showed the typical clinical, histopathological, and immunological characteristics of the non-inflammatory type of DPP4i-BP. Although the pathogenesis of thermal burn-induced BP and DPP4i-BP remains uncertain, BP may occur due to various triggering factors.

ETHICS STATEMENT

This report on a single patient complies with the Declaration of Helsinki. The patient gave written informed consent for the publication of this report.

REFERENCES

1. Izumi K, Nishie W, Mai Y, Wada M, Natsuga K, Ujiie H, et al. Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid. J Invest Dermatol (2016) 136:2201–10. doi:10.1111/jid.2016.06.622
2. Murrell DF, Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol (2012) 66:479–85. doi:10.1016/j.jaad.2011.06.032
3. Schmidt E, Zillikens D. Pemphigoid diseases. Lancet (2013) 380:320–32. doi:10.1016/S0140-6736(12)61440-4
4. Linagliptin-associated bullous pemphigoid that was most likely caused by IgG autoantibodies against the midportion of BP180. Br J Dermatol (2017) 176:541–3. doi:10.1111/bjd.15111
5. Mul VE, van Geest AJ, Pijls-Johannesma MC, Theys J, Verschueren TA, Jager JJ, et al. Radiation-induced bullous pemphigoid: a systematic review of an unusual radiation side effect. Radiother Oncol (2007) 82:5–9. doi:10.1016/j.radonc.2006.11.014
6. Cabrera-Rodríguez JJ, Muñoz-García JL, Quirós Rivero J, Ropero Carmona F, Ríos Kavaday Y. Radio-induced bullous pemphigoid. Clin Transl Oncol (2010) 12:66–8. doi:10.1007/s12094-010-0469-9
7. Zhou X, Velez NE, Farsani T, Tsiaras W, Laga AC, Werchniak AE, et al. Multiple tense bullae localized to the right breast in a woman in her seventies. JAMA Dermatol (2013) 149:1427–8. doi:10.1001/jamadermatol.2013.4704
8. Béné J, Moulis G, Bennani I, Auftret M, Coupe P, Babai S, et al. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French pharmacovigilance database. Br J Dermatol (2016) 175:296–301. doi:10.1111/bjd.14601
9. Sakai A, Shimomura Y, Ansai O, Saito Y, Tomii K, Tsuchiya Y, et al. Linagliptin-associated bullous pemphigoid that was most likely caused by IgG autoantibodies against the midportion of BP180. Br J Dermatol (2017) 176:541–3. doi:10.1111/bjd.15111
10. Mul VE, van Geest AJ, Pijls-Johannesma MC, Theys J, Verschueren TA, Jager JJ, et al. Radiation-induced bullous pemphigoid: a systematic review of an unusual radiation side effect. Radiother Oncol (2007) 82:5–9. doi:10.1016/j.radonc.2006.11.014
11. Cabrera-Rodríguez JJ, Muñoz-García JL, Quirós Rivero J, Ropero Carmona F, Ríos Kavaday Y. Radio-induced bullous pemphigoid. Clin Transl Oncol (2010) 12:66–8. doi:10.1007/s12094-010-0469-9
12. Olisha O, Lijoretzky G, Grenader T. Bullous pemphigoid following adjuvant radiotherapy for breast cancer. Breast J (2011) 17:204–5. doi:10.1111/j.1524-4741.2010.01060.x
13. Zhou X, Velez NE, Farsani T, Tsiaras W, Laga AC, Werchniak AE, et al. Multiple tense bullae localized to the right breast in a woman in her seventies. JAMA Dermatol (2013) 149:1427–8. doi:10.1001/jamadermatol.2013.4704
14. Nieder C, Al-Shibli K, Tollåli T. Nontargeted effect after radiotherapy in a patient with non-small cell lung cancer and bullous pemphigoid. Case Rep Oncol Med (2015) 2015:964687. doi:10.1155/2015/964687
15. Campa M, Mansouri B, Wilcox B, Griffin JR. Radiation-induced localized bullous pemphigoid in a patient with breast carcinoma. Dermatol Online J (2016) 22.

AUTHOR CONTRIBUTIONS

YM, WN, and Kizumi drafted the paper. KS, MH, Khto, and KH were involved in treating the patient and collecting the clinical data. HS supervised the writing of the manuscript.

ACKNOWLEDGMENTS

The authors thank the patient and express their appreciation to Hiroko Azuma for her technical assistance.

FUNDING

This work was supported in part by a Grant-in-Aid for Scientific Research (B) (#24390274 to WN) and Challenging Exploratory Research (#15K15409 to WN).

TABLE 2 | Overview of thermal burn-induced bullous pemphigoid (BP) cases.

| No. | Age | Sex | BP180 | BP230 | Diagnosis | Eruption | Delay after burn | Relapse | Reference |
|-----|-----|-----|-------|-------|-----------|----------|-----------------|---------|-----------|
| 1   | 80  | M   | HE, DIF, IIF | Localized | 2 weeks | Not mentioned | Jevtic and Grigoris (62) |
| 2   | 69  | M   | HE | Generalized | 3 weeks | Not mentioned | Quartey-Papafio and Hudson (63) |
| 3   | 75  | F   | HE | Generalized | 10 weeks | No | Balato et al. (54) |
| 4   | 79  | M   | HE, DIF, ssIIF | Localized | 1 month | No | Vassileva et al. (65) |
| 5   | 74  | M   | HE, DIF | Localized | 8 months | No | Wagner et al. (66) |
| 6   | 67  | M   | HE | Generalized | 2 days | Yes | Dañescu et al. (5) |
| 7   | 51  | M   | NC16A (−) | HE, DIF, ssIIF | Generalized | 6 weeks | No | Xu et al. (67) |
| 8   | 68  | F   | HE, DIF, ssIIF | Generalized | A few days | No | Korfitis et al. (38) |
| 9   | 74  | M   | HE, DIF | Generalized | 2 weeks | No | Bachmeyer et al. (58) |
| 10  | 85  | F   | NC16A | Generalized | 20 months | No | Neri et al. (60) |
| 11  | 73  | F   | HE, DIF | Localized | 6 weeks | No | Damevska et al. (60) |
| 12  | 89  | F   | HE, DIF | Generalized | 69 years | No | Morita et al. (61) |
| 13  | 76  | M   | NC16A (−) | HE, DIF, ssIIF | Generalized | A few hours | No | Wagner et al. (66) |
| Our case | 60 M | Non-NC16A | HE, DIF | Generalized | 2 days | Yes | Dañescu et al. (5) |

M, male; F, female; HE, hematoxylin and eosin stain; DIF, direct immunofluorescence; IIF, indirect immunofluorescence; ssIIF, 1 M NaCl-split skin indirect immunofluorescence.
16. Shon W, Wada DA, Kalaaji AN. Radiation-induced pemphigus or pemphigus erythematosus in 3 patients with distinct underlying malignancies. *Citus* (2016) 92:21–22.

17. Hirotsu K, Chiou AS, Chiang A, Kim J, Kwong BY, Pugliese S. Localized bullous pemphigoid in a melanoma patient with dual exposure to PD-1 checkpoint inhibition and radiation therapy. *JAAD Case Rep* (2017) 3:404–6. doi:10.1016/j.jcder.2017.06.004

18. Roeder C, Driesch PV. Pсориatic erythroderma and bullous pemphigoid treated successfully with acitretin and azathioprine. *Eur Dermatol* (1999) 9:537–9.

21. Kluger N, Mandelin J, Santi K, Jeskanen L, Nuutinen P. Bullous pemphigoid triggered by radiotherapy for breast cancer. *Presse Med* (2017) 46:128–30. doi:10.1016/lpm.2016.09.019

29. Riyaz N, Nasir N, Bindu V, Sasidharanpillai S. Bullous pemphigoid induced by psoralen plus ultraviolet A therapy. *Photodermatol Photoimmunol Photomed* (2008) 24:300–2. doi:10.1002/pdp.200800415

31. Asbrink E, Hovmark A. Clinical variations in bullous pemphigoid with respect to sites of burns (scalds) in a patient on sulphasalazine for ulcerative colitis. *Clin Exp Dermatol* (2008) 33:154–5. doi:10.1111/j.1365-2200.2007.02603.x

34. Riyaz N, Nasir N, Bindu V, Sasidharanpillai S. Bullous pemphigoid induced by psoralen plus ultraviolet A therapy. *Clin Exp Dermatol* (2008) 33:154–5. doi:10.1111/j.1365-2200.2007.02603.x

37. Murphy R, Walsh M, McKenna K. Bullous pemphigoid arising in lower leg vein graft incision site. *J Card Surg* (2016) 31:57–9. doi:10.1111/jocs.12668

41. Cavazzani A, Hoz JC, Massa MC, Freeark RJ. Poxviridae. *J Am Acad Dermatol* (2011) 64:1–26. doi:10.1016/j.jaad.2011.03.059

45. Ooi E, Devuyst V, Arrossi N, Chosidow O, et al. Poxviridae. *J Am Acad Dermatol* (2011) 64:1–26. doi:10.1016/j.jaad.2011.03.059

48. Nozu T, Mita H. Bullous pemphigoid and percutaneous endoscopic gastrostomy. *Intern Med* (2010) 49:971–5. doi:10.1016/j.intermed.2009.10.003

51. Santti K, Jeskanen L, Nuutinen P. Bullous pemphigoid in surgical wounds. *Clin Exp Dermatol* (2008) 33:154–5. doi:10.1111/j.1365-2200.2007.02603.x

54. Levison DL, Sadjwani A. Blistering on a squamous cell carcinoma graft site in a patient with bullous pemphigoid. *Citus* (1994) 54:40.
66. Hafejee A, Coulson IH. Localized bullous pemphigoid 20 years after split skin grafting. *Clin Exp Dermatol* (2005) 30:187–8. doi:10.1111/j.1365-2230.2004.01689.x
67. Orvis AK, Ihnatsenka V, Hatch RL. Bullous lesions on a skin graft donor site. *J Am Board Fam Med* (2009) 22:89–92. doi:10.3122/jabfm.2009.01.080036
68. Sparrow GP, Moynahan EJ. Localized pemphigoid. *Br J Dermatol* (1976) 14:26–8.
69. Dahl MG, Cook LJ. Lesions induced by trauma in pemphigoid. *Br J Dermatol* (1979) 101:469–73. doi:10.1111/j.1365-2133.1979.tb00029.x
70. Macfarlane AW, Verbov JL. Trauma-induced bullous pemphigoid. *Clin Exp Dermatol* (1989) 14:245–9. doi:10.1111/j.1365-2230.1989.tb00944.x
71. Twine CP, Malik G, Street S, Williams IM. Bullous pemphigoid presenting as dry gangrene in a revascularized limb. *J Vasc Surg* (2010) 51:732–4. doi:10.1016/j.jvs.2009.10.110
72. Rakvit P, Kerr AC, Ibbotson SH. Localized bullous pemphigoid induced by photodynamic therapy. *Photodermatol Photoimmunol Photomed* (2011) 27:251–3. doi:10.1111/j.1600-0781.2011.00609.x
73. Ujiie H, Muramatsu K, Mushiroda T, Ozeki T, Miyoshi H, Iwata H, et al. HLA-DQB1*03:01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP-4 inhibitors. *J Invest Dermatol* (2017) (in press). doi:10.1016/j.jid.2017.11.023
74. Danno K, Takigawa M, Horio T. The alterations of keratinocyte surface and basement membrane markers by treatment with 8-methoxypsoralen plus long-wave ultraviolet light. *J Invest Dermatol* (1983) 80:172–4. doi:10.1111/1523-1747.ep12533415
75. Amber KT, Zikry J, Hertl M. A multi-hit hypothesis of bullous pemphigoid and associated neurological disease: is HLA-DQB1*03:01, a potential link between immune privileged antigen exposure and epitope spreading? *HLA* (2017) 89:127–34. doi:10.1111/tan.12960

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

**Copyright © 2018 Mai, Nishie, Sato, Hotta, Izumi, Ito, Hosokawa and Shimizu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**